Reata Readies Bardoxolone For Phase III Looking At Kidney Function Outcomes
This article was originally published in The Pink Sheet Daily
Executive Summary
Further Phase II data show biomarker evidence, and Reata will now look to a 1,600-patient Phase III trial to prove the drug can lead to improved kidney function.